|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GAGE2A |
Gene summary for GAGE2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GAGE2A | Gene ID | 729447 |
| Gene name | G antigen 2A | |
| Gene Alias | CT4.2 | |
| Cytomap | Xp11.23 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q6NT46 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 729447 | GAGE2A | HCC1_Meng | Human | Liver | HCC | 2.60e-139 | 1.47e+00 | 0.0246 |
| 729447 | GAGE2A | HCC2 | Human | Liver | HCC | 2.08e-08 | 2.09e+00 | 0.5341 |
| 729447 | GAGE2A | S014 | Human | Liver | HCC | 9.74e-67 | 3.13e+00 | 0.2254 |
| 729447 | GAGE2A | S015 | Human | Liver | HCC | 3.46e-35 | 3.10e+00 | 0.2375 |
| 729447 | GAGE2A | S016 | Human | Liver | HCC | 1.08e-79 | 3.60e+00 | 0.2243 |
| 729447 | GAGE2A | S028 | Human | Liver | HCC | 2.27e-11 | 8.96e-01 | 0.2503 |
| 729447 | GAGE2A | C57 | Human | Oral cavity | OSCC | 2.06e-58 | 1.92e+00 | 0.1679 |
| 729447 | GAGE2A | SYSMH1 | Human | Oral cavity | OSCC | 8.94e-95 | 2.02e+00 | 0.1127 |
| 729447 | GAGE2A | ATC09 | Human | Thyroid | ATC | 2.96e-25 | 1.16e+00 | 0.2871 |
| 729447 | GAGE2A | ATC1 | Human | Thyroid | ATC | 2.06e-28 | 1.34e+00 | 0.2878 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GAGE2A | SNV | Missense_Mutation | c.175N>G | p.Gln59Glu | p.Q59E | Q6NT46 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0T7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| GAGE2A | SNV | Missense_Mutation | novel | c.154N>A | p.Pro52Thr | p.P52T | Q6NT46 | protein_coding | tolerated(0.53) | possibly_damaging(0.895) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| GAGE2A | SNV | Missense_Mutation | novel | c.50N>C | p.Val17Ala | p.V17A | Q6NT46 | protein_coding | tolerated(0.06) | benign(0.257) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GAGE2A | SNV | Missense_Mutation | novel | c.112N>T | p.Ala38Ser | p.A38S | Q6NT46 | protein_coding | tolerated(0.62) | benign(0.062) | TCGA-44-7661-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |